Clinical Trial Update: Erythrocyte-Mediated Drug Delivery for the Prevention of Stent Restenosis [Phase 4]

View source ↗

Summary

This Phase 4 clinical trial, sponsored by the University of Rome Tor Vergata, evaluates erythrocyte-mediated drug delivery to prevent restenosis after stent pla…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis

Snippet

Sponsor: University of Rome Tor Vergata | Conditions: Atherosclerosis, Acute-Phase Reaction | Phase 4 | Status: UNKNOWN